Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

Selumetinib Sulfate

Selumetinib Sulfate API

Selumetinib Sulfate-API

CAS Number: 943332-08-9

Therapeutic Category
Anti-Cancer/ Oncology
API Technology
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Innovator Brand (USA)

Mechanism of Action

Selumetinib sulfate is a kinase inhibitor, a type of medication that works by blocking the activity of certain enzymes called kinases. Selumetinib sulfate specifically targets two kinases, MEK1 and MEK2, which play a critical role in the signaling pathways that regulate cell growth and division.

In cancer cells, mutations in genes that regulate these signaling pathways can lead to their overactivity, driving the uncontrolled growth and division of the cells. Selumetinib sulfate works by blocking the activity of MEK1/2, thereby interrupting these abnormal signaling pathways and slowing down the progression of the cancer.

Selumetinib sulfate is used to treat certain types of cancer, including non-small cell lung cancer, hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC), and neurofibromatosis type 1-associated plexiform neurofibromas. The drug is administered orally and works by targeting the cancer cells directly, reducing their ability to grow and divide.


Selumetinib sulfate is a medication used for the treatment of certain types of cancer. It is indicated for the treatment of:

Non-small cell lung cancer (NSCLC): Selumetinib sulfate is indicated for the treatment of adult patients with NSCLC whose tumors have a specific genetic mutation (BRAF V600E).

Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC): Selumetinib sulfate is indicated for the treatment of adult patients with HLRCC-associated renal cell carcinoma.

Neurofibromatosis type 1-associated plexiform neurofibromas: Selumetinib sulfate is indicated for the treatment of adult and pediatric patients 2 years of age and older with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Selumetinib Sulfate API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Selumetinib Sulfate API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Oncology API Products:

Learn More

Contact Us

Please fill in the following form for API Requirement & we'll get back to you shortly

We are here to help, if you have any country specific requirements.


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.